This years 2026 ASCO Gastrointestinal Cancers Symposium was packed with practice-shaping data across colorectal and upper ...
The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...
In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the clinical necessity of overcoming resistance to first-generation EGFR ...
Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV ...
Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...
In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...
Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to invest in now. On January 27, Cantor Fitzgerald raised the firm’s price target on Pfizer to $27 from $24 and maintained a ...
The global oncology sector is rocketing toward $668 billion in 2034[1], partly fueled by a massive structural pivot toward gastrointestinal ...
MedPage Today on MSN
Targeted duo wins again in BRAF-mutant colorectal cancer
Response rates with encorafenib-cetuximab plus FOLFIRI similar to combo plus modified FOLF ...
FDA approves Guardant Health's blood test to help identify metastatic colorectal cancer patients eligible for targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results